Skip to main content

Advertisement

SpringerLink
Log in

Management of neuroendocrine tumors of unknown primary

  • Published:
Reviews in Endocrine and Metabolic Disorders Aims and scope Submit manuscript

Abstract

Neuroendocrine neoplams (NENs) are mostly relatively indolent malignancies but a significant number have metastatic disease at diagnosis mainly to the liver. Although in the majority of such cases the primary origin of the tumor can be identified, in approximately 11–22% no primary tumor is found and such cases are designated as NENs of unknown primary origin (UPO). This has significant therapeutic implications with respect to potentially resectable hepatic disease and/or application of appropriate medical therapy, either chemotherapeutic agents or targeted treatment, as the response to various treatments varies according to the origin of the primary tumor. This lack of tumor specific orientated treatment may also account for the relatively poorer prognosis of NENs of UPO compared to metastatic NENs with a known primary site. In the majority of cases the primary tumors are located in the small bowel and the lung, but a number may still elude detection. Occasionally the presence of a functional syndrome may direct to the specific tissue of origin but in the majority of cases a number of biochemical, imaging, histopathological and molecular modalities are utilized to help identify the primary origin of the tumor and direct treatment accordingly. Several diagnostic algorithms have recently been developed to help localize an occult primary tumor; however, in a number of cases no lesion is identified even after prolonged follow-up. It is expected that the delineation of the molecular signature of the different NENs may help identify such cases and provide appropriate treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3(10):1335–42.

    Article  PubMed  Google Scholar 

  2. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008;9:61–72.

    Article  CAS  PubMed  Google Scholar 

  3. Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al. ENETS consensus guidelines update for the Management of Distant Metastatic Disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103:172–85.

    Article  CAS  PubMed  Google Scholar 

  4. Partelli S, Bartsch DK, Capdevila J, Chen J, Knigge U, Niederle B, et al. ENETS consensus guidelines for standard of Care in Neuroendocrine Tumours: surgery for small intestinal and pancreatic neuroendocrine Tumours. Neuroendocrinology. 2017;105:255–65.

    Article  CAS  PubMed  Google Scholar 

  5. Catena L, Bichisao E, Milione M, Valente M, Platania M, Pusceddu S, et al. Neuroendocrine tumors of unknown primary site: gold dust or misdiagnosed neoplasms? Tumori. 2011;97:564–7.

    Article  PubMed  Google Scholar 

  6. Hauso O, Gustafsson BI, Kidd M, Waldum HL, Drozdov I, Chan AK, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2008;113:2655–64.

    Article  PubMed  Google Scholar 

  7. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008;26:3063–72.

    Article  PubMed  Google Scholar 

  8. Wang SC, Parekh JR, Zuraek MB, Venook AP, Bergsland EK, Warren RS, et al. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg. 2010;145:276–80.

    Article  PubMed  Google Scholar 

  9. Bhosale P, Shah A, Wei W, Varadhachary G, Johnson V, Shah V, et al. Carcinoid tumours: predicting the location of the primary neoplasm based on the sites of metastases. Eur Radiol. 2013;23:400–7.

    Article  CAS  PubMed  Google Scholar 

  10. Massimino KP, Han E, Pommier SJ, Pommier RF. Laparoscopic surgical exploration is an effective strategy for locating occult primary neuroendocrine tumors. Am J Surg. 2012;203:628–31.

    Article  PubMed  Google Scholar 

  11. Wang YZ, Chauhan A, Rau J, Diebold AE, Opoku-Boateng A, Ramcharan T, et al. Neuroendocrine tumors (NETs) of unknown primary: is early surgical exploration and aggressive debulking justifiable? Chin Clin Oncol. 2016;5:4.

    PubMed  Google Scholar 

  12. Antunes P, Ginj M, Zhang H, Waser B, Baum RP, Reubi JC, et al. Are radiogalliumlabelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur J Nucl Med Mol Imaging. 2007;34:982–93.

    Article  CAS  PubMed  Google Scholar 

  13. Pruthi A, Pankaj P, Verma R, Jain A, Belho ES, Mahajan H. Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in India. J Gastrointest Oncol. 2016;7:449–61.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT. Eur J Nucl Med Mol Imaging. 2010;37:67–77.

    Article  CAS  PubMed  Google Scholar 

  15. Naswa N, Sharma P, Kumar A, Soundararajan R, Kumar R, Malhotra A, et al. 68Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin. Clin Nucl Med. 2012;37:245–51.

    Article  PubMed  Google Scholar 

  16. Givi B, Pommier SJ, Thompson AK, Diggs BS, Pommier RF. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. Surgery. 2006;140:891–7. discussion 897-8

    Article  PubMed  Google Scholar 

  17. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev. 2004;25:458–511.

    Article  CAS  PubMed  Google Scholar 

  18. Grossman AB, Kelly P, Rockall A, Bhattacharya S, McNicol A, Barwick T. Cushing's syndrome caused by an occult source: difficulties in diagnosis and management. Nat Clin Pract Endocrinol Metab. 2006;2:642–7.

    Article  PubMed  Google Scholar 

  19. Singer J, Werner F, Koch CA, Bartels M, Aigner T, Lincke T, et al. Ectopic Cushing's syndrome caused by a well differentiated ACTH-secreting neuroendocrine carcinoma of the ileum. Exp Clin Endocrinol Diabetes. 2010;118:524–9.

    Article  CAS  PubMed  Google Scholar 

  20. Fasshauer M, Lincke T, Witzigmann H, Kluge R, Tannapfel A, Moche M, et al. Ectopic Cushing' syndrome caused by a neuroendocrine carcinoma of the mesentery. BMC Cancer. 2006;6:108.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Dimitriadis GK, Angelousi A, Weickert MO, Randeva HS, Kaltsas G, Grossman A. Paraneoplastic endocrine syndromes. Endocr Relat Cancer. 2017;24:R173–90.

    Article  PubMed  Google Scholar 

  22. Passaro E Jr, Howard TJ, Sawicki MP, Watt PC. Stabile BE the origin of sporadic gastrinomas within the gastrinoma triangle: a theory. Arch Surg. 1998;133(1):13–6. discussion 17

    Article  PubMed  Google Scholar 

  23. Hannah-Shmouni F, Stratakis CA, Koch CA. Flushing in (neuro)endocrinology. Rev Endocr Metab Disord. 2016;17:373–80.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med. 1999;340:858–68.

    Article  CAS  PubMed  Google Scholar 

  25. Alexandraki KI, Kaltsas G. Gastroenteropancreatic neuroendocrine tumors: new insights in the diagnosis and therapy. Endocrine. 2012;41:40–52.

    Article  CAS  PubMed  Google Scholar 

  26. Tellez MR, Mamikunian G, O'Dorisio TM, Vinik AI, Woltering EAA. Single fasting plasma 5-HIAA value correlates with 24-hour urinary 5-HIAA values and other biomarkers in midgut neuroendocrine tumors (NETs). Pancreas. 2013;42:405–10.

    Article  CAS  PubMed  Google Scholar 

  27. Diebold AE, Boudreaux JP, Wang YZ, Anthony LB, Uhlhorn AP, Ryan P, et al. Levels predict survival in patients with stage IV well differentiated small bowel neuroendocrine neoplasms. Surgery. 2012;152:1172–6.

    Article  PubMed  Google Scholar 

  28. Sundin A, Vullierme MP, Kaltsas G, Plöckinger U, Mallorca Consensus Conference participants., European Neuroendocrine Tumor Society. ENETS consensus guidelines for the standards of Care in Neuroendocrine Tumors: radiological examinations. Neuroendocrinology. 2009;90:167–83.

    Article  CAS  PubMed  Google Scholar 

  29. Sundin A, Arnold R, Baudin E, Cwikla JB, Eriksson B, Fanti S, et al. ENETS consensus guidelines for the standards of Care in Neuroendocrine Tumors: radiological, nuclear medicine and hybrid imaging. Neuroendocrinology. 2017;105:212–44.

    Article  CAS  PubMed  Google Scholar 

  30. Sugimoto E, Lorelius LE, Eriksson B, Oberg K. Midgut carcinoid tumours: CT appearance. Acta Radiol. 1995;36(4-6):367–71.

    Article  CAS  PubMed  Google Scholar 

  31. Yordanova A, Ahmadzadehfar H, Gonzalez-Carmona M, Strassburg C, Mayer K, Feldmann G, et al. Step-by-step clinical approach for the Management of Neuroendocrine Tumours. Horm Metab Res. 2017;49:77–85.

    Article  CAS  PubMed  Google Scholar 

  32. Johanssen S, Boivin M, Lochs H, Voderholzer W. The yield of wireless capsule endoscopy in the detection of neuroendocrine tumors in comparison with CT enteroclysis. Gastrointest Endosc. 2006;63:660–5.

    Article  PubMed  Google Scholar 

  33. van Tuyl SA, van Noorden JT, Timmer R, Stolk MF, Kuipers EJ, Taal BG. Detection of small-bowel neuroendocrine tumors by video capsule endoscopy. Gastrointest Endosc. 2006;64:66–72.

    Article  PubMed  Google Scholar 

  34. Kamaoui I, De-Luca V, Ficarelli S, Mennesson L-BC, Pilleul F. Value of CT enteroclysis in suspected small-bowel carcinoidtumors. AJR. 2010;194(3):629–33. https://doi.org/10.2214/AJR.09.2760.

    Article  PubMed  Google Scholar 

  35. Hakim FA, Alexander JA, Huprich JE, Grover M, Enders FT. CT-enterography may identify small bowel tumors not detected by capsule endoscopy: eight years experience at Mayo Clinic Rochester. Dig Dis Sci. 2011;56:2914–9.

    Article  PubMed  Google Scholar 

  36. Ganeshan D, Bhosale P, Yang T, Kundra V. Imaging features of carcinoid tumors of the gastrointestinal tract. AJR Am J Roentgenol. 2013;201:773–86.

    Article  PubMed  Google Scholar 

  37. Bellutti M, Fry LC, Schmitt J, Seemann M, Klose S, Malfertheiner P, et al. Detection of neuroendocrine tumors of the small bowel by double balloon enteroscopy. Dig Dis Sci. 2009;54:1050–8.

    Article  PubMed  Google Scholar 

  38. Dohan A, El Fattach H, Barat M, Guerrache Y, Eveno C, Dautry R, et al. Neuroendocrine tumors of the small bowel: evaluation with MR-enterography. Clin Imaging. 2016;40:541–7.

    Article  PubMed  Google Scholar 

  39. Vinik AI, Woltering EA, Warner RR, Caplin M, O'Dorisio TM, Wiseman GA, et al. NANETS consensus guidelines for the diagnosis of neuroendocrine tumor. Pancreas. 2010;39:713–34.

    Article  PubMed  Google Scholar 

  40. Imamura M, Komoto I. Gastrinoma. In: Hubbard J, Inabnet WB, LoC-Y, editors. Endocrine surgery: Principles and Practice, Springer Science & Business Media, 2009, pp 508–518.

  41. Jensen RT, Rindi G, Arnold R, Lopes JM, Brandi ML, Bechstein WO, et al. Well-differentiated duodenal tumor/carcinoma (excluding gastrinomas). Neuroendocrinology. 2006;84:165–72.

    Article  CAS  PubMed  Google Scholar 

  42. Kann PH, Wirkus B, Keth A, Goitom K. Pitfalls in endosonographic imaging of suspected insulinomas: pancreatic nodules of unknown dignity. Eur J Endocrinol. 2003;148:531–4.

    Article  CAS  PubMed  Google Scholar 

  43. Müssig K, Wehrmann M, Horger M, Bares R, Häring HU, Gallwitz B, et al. Lymph node gastrinoma in multiple endocrine neoplasia type 1 - a diagnostic challenge. Exp Clin Endocrinol Diabetes. 2008;116:554–7.

    Article  PubMed  Google Scholar 

  44. Ramage JK, De Herder WW, Delle Fave G, Ferolla P, Ferone D, Ito T, et al. Vienna consensus conference participants. ENETS consensus guidelines update for colorectal neuroendocrine neoplasms. Neuroendocrinology. 2016;103:139–43.

    Article  CAS  PubMed  Google Scholar 

  45. Rösch T, Lightdale CJ, Botet JF, Boyce GA, Sivak MV Jr, Yasuda K, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med. 1992;326:1721–6.

    Article  PubMed  Google Scholar 

  46. De Angelis C, Carucci P, Repici A, Rizzetto M. Endosonography in decision making and management of gastrointestinal endocrine tumors. Eur J Ultrasound. 1999;10:139–50.

    Article  PubMed  Google Scholar 

  47. James PD, Tsolakis AV, Zhang M, Belletrutti PJ, Mohamed R, Roberts DJ, et al. Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis. Gastrointest Endosc. 2015;81:848–56.

    Article  PubMed  Google Scholar 

  48. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0, Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–30.

    Article  CAS  PubMed  Google Scholar 

  49. Tirosh A, Papadakis GZ, Millo C, Sadowski SM, Herscovitch P, Pacak K, et al. Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total 68Ga-DOTATATE-avid tumor volume measurements. Eur J Endocrinol. 2017;176:575–82.

    Article  CAS  PubMed  Google Scholar 

  50. Kirshbom PM, Kherani AR, Onaitis MW, Feldman JM, Tyler DS. Carcinoids of unknown origin: comparative analysis with foregut, midgut, and hindgut carcinoids. Surgery. 1998;124:1063–70.

    Article  CAS  PubMed  Google Scholar 

  51. Sampathirao N, Basu S. MIB-1 index-stratified assessment of dual-tracer PET/CT with 68Ga-DOTATATE and 18F-FDG and multimodality anatomic imaging in metastatic neuroendocrine tumors of UnknownPrimary in a PRRT workup setting. J Nucl Med Technol. 2017;45:34–41.

    Article  PubMed  Google Scholar 

  52. Maxwell JE, Sherman SK, Stashek KM, O'Dorisio TM, Bellizzi AM, Howe JR. A practical method to determine the site of unknown primary in metastatic neuroendocrine tumors. Surgery. 2014;156:1359–65. discussion 1365-6

    Article  PubMed  PubMed Central  Google Scholar 

  53. Yang Z, Klimstra DS, Hruban RH, Tang LH. Immunohistochemical characterization of the origins of metastatic well-differentiated neuroendocrine tumors to the liver. Am J Surg Pathol. 2017;41:915–22.

    Article  PubMed  Google Scholar 

  54. Lai JP, Mertens RB, Mirocha J, Koo J, Venturina M, Chung F, et al. Comparison of PAX6 and PAX8 as immunohistochemical markers for pancreatic neuroendocrine tumors. Endocr Pathol. 2015;26:54–62.

    Article  CAS  PubMed  Google Scholar 

  55. Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnostic immunohistochemistry. Adv Anat Pathol. 2013;20:285–314.

    Article  CAS  PubMed  Google Scholar 

  56. Srivastava A, Hornick JL. Immunohistochemical staining for CDX-2, PDX-1, NESP-55, and TTF-1 can help distinguish gastrointestinal carcinoid tumors from pancreatic endocrine and pulmonary carcinoid tumors. Am J Surg Pathol. 2009;33:626–32.

    Article  PubMed  Google Scholar 

  57. Hermann G, Konukiewitz B, Schmitt A, Perren A, Klöppel G. Hormonally defined pancreatic and duodenal neuroendocrine tumors differ in their transcription factor signatures: expression of ISL1, PDX1, NGN3, and CDX2. Virchows Arch. 2011;459:147–54.

    Article  CAS  PubMed  Google Scholar 

  58. Chan ES, Alexander J, Swanson PE, Jain D, Yeh MM. PDX-1, CDX-2, TTF-1, and CK7: a reliable immunohistochemical panel for pancreatic neuroendocrine neoplasms. Am J Surg Pathol. 2012;36:737–43.

    Article  PubMed  Google Scholar 

  59. Fendrich V, Ramerth R, Waldmann J, Maschuw K, Langer P, Bartsch DK, et al. Sonic hedgehog and pancreatic-duodenal homeobox 1 expression distinguish between duodenal and pancreatic gastrinomas. Endocr Relat Cancer. 2009;16:613–22.

    Article  CAS  PubMed  Google Scholar 

  60. Yazdani S, Kasajima A, Ogata H, Felizola SJ, Nakamura Y, Onodera Y, et al. Progesterone receptor isoforms A and B in pancreatic neuroendocrine tumor. Neuroendocrinology. 2015;101:309–20.

    Article  CAS  PubMed  Google Scholar 

  61. Yadav R, Kakkar A, Sharma A, Malik PS, Sharma MC. Study of clinicopathological features, hormone immunoexpression, and loss of ATRX and DAXX expression in pancreatic neuroendocrine tumors. Scand J Gastroenterol. 2016;51:994–9.

    Article  CAS  PubMed  Google Scholar 

  62. Inzani F, Petrone G, Fadda G, Rindi G. Cyto-histology in NET: what is necessary today and what is the future? Rev Endocr Metab Disord. 2017; https://doi.org/10.1007/s11154-017-9428-x.

  63. Kaemmerer D, Posorski N, von Eggeling F, Ernst G, Hörsch D, Baum RP, et al. The search for the primary tumor in metastasized gastroenteropancreatic neuroendocrine neoplasm. Clin Exp Metastasis. 2014;31:817–2.

    Article  CAS  PubMed  Google Scholar 

  64. Posorski N, Kaemmerer D, Ernst G, Grabowski P, Hoersch D, Hommann M, et al. Localization of sporadic neuroendocrine tumors by gene expression analysis of their metastases. Clin Exp Metastasis. 2011;28:637–47.

    Article  CAS  PubMed  Google Scholar 

  65. Karpathakis A, Dibra H, Pipinikas C, Feber A, Morris T, Francis J, et al. Progressive epigenetic dysregulation in neuroendocrine tumour liver metastases. Endocr Relat Cancer. 2017;24:L21–5.

    Article  CAS  PubMed  Google Scholar 

  66. Polish A, Vergo MT, Agulnik M. Management of neuroendocrine tumors of unknown origin. J Natl Compr Cancer Netw. 2011;9:1397–402. quiz 1403

    Article  Google Scholar 

  67. NCCN Clinical practice guidelines in oncology. Neuroendocrine tumors, version 1. 2015. Available online: http://www.jnccn.org/content/13/1/78.abstract

  68. Rinke A, Müller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebocontrolled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009;28:4656–63.

    Article  Google Scholar 

  69. Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–33.

    Article  PubMed  Google Scholar 

  70. Pavel M, Valle JW, Eriksson B, Rinke A, Caplin M, Chen J, et al. ENETS consensus guidelines for the standards of Care in Neuroendocrine Neoplasms: systemic therapy - biotherapy and novel targeted agents. Neuroendocrinology. 2017;105(3):266–80.

    Article  CAS  PubMed  Google Scholar 

  71. Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, et al. Efficacy of rad001 (everolimus) and octreotide lar in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase ii study. J Clin Oncol. 2008;26:4311–8.

    Article  PubMed  PubMed Central  Google Scholar 

  72. Singh S, Carnaghi C, Buzzoni R, Pommier RF, Raderer M, Tomasek J, et al. Everolimus in Neuroendocrine Tumors of the Gastrointestinal Tract and Unknown Primary. Neuroendocrinology. 2017; https://doi.org/10.1159/000477585.

  73. Garcia-Carbonero R, Rinke A, Valle JW, Fazio N, Caplin M, Gorbounova V, et al. ENETS consensus guidelines for the standards of Care in Neuroendocrine Neoplasms. Systemic therapy 2: chemotherapy. Neuroendocrinology. 2017;105:281–94.

    Article  CAS  PubMed  Google Scholar 

  74. Angelousi A, Kaltsas G, Koumarianou A, Weickert MO, Grossman A. Chemotherapy in NETs: when and how. Rev Endocr Metab Disord. 2017; https://doi.org/10.1007/s11154-017-9432-1.

  75. Deutschbein T, Unger N, Yuece A, Eberhardt W, Gauler T, Lahner H, et al. Chemotherapy in patients with progressive, undifferentiated neuroendocrine tumors: a single-center experience. Horm Metab Res. 2011;43:838–43.

    Article  CAS  PubMed  Google Scholar 

  76. Alexandraki KI, Karapanagioti A, Karoumpalis I, Boutzios G, Kaltsas GA. Advances and current concepts in the medical management of gastro-Entero-pancreatic (GEP) neuroendocrine neoplasms. Biomed Res Int. 2017;2017:12.

  77. Thapa P, Ranade R, Ostwal V, Shrikhande SV, Goel M, Basu S. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics. Nucl Med Commun. 2016;37:1030–7.

    Article  CAS  PubMed  Google Scholar 

  78. Scharf M, Petry V, Daniel H, Rinke A, Gress TM. Bone metastases in NEN patients. Neuroendocrinology. 2017; https://doi.org/10.1159/000457954.

  79. Niederle B, Pape UF, Costa F, Gross D, Kelestimur F, Knigge U, et al. Vienna consensus conference participants. ENETS consensus guidelines update for neuroendocrine neoplasms of the jejunum and ileum. Neuroendocrinology. 2016;103:125–38.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Endocrinology, Department of Pathophysiology, Medical School, National and Kapodistrian University of Athens, Athens, Greece

    Krystallenia Alexandraki, Anna Angelousi, Georgios Boutzios & Gregory Kaltsas

  2. Department of Pathology, Evangelismos Hospital, Athens, Greece

    Georgios Kyriakopoulos & Dimitra Rontogianni

Authors
  1. Krystallenia Alexandraki
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Anna Angelousi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Georgios Boutzios
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Georgios Kyriakopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dimitra Rontogianni
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Gregory Kaltsas
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gregory Kaltsas.

Ethics declarations

Conflict of interest statement

The authors have nothing to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alexandraki, K., Angelousi, A., Boutzios, G. et al. Management of neuroendocrine tumors of unknown primary. Rev Endocr Metab Disord 18, 423–431 (2017). https://doi.org/10.1007/s11154-017-9437-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11154-017-9437-9

Keywords

Search

Navigation